Clinical trial · Interventional
Esketamine for Prevention of Depression After Cytoreductive Surgery in Ovarian Cancer
Intraoperative Esketamine for Prevention of Depressive Symptoms After Cytoreductive Surgery in Ovarian Cancer: a Controlled, Randomized Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer. The main questions it aims to answer are: * Whether a single low dose of esketamine administered would reduce the postoperative depressive symptoms three days after cytoreductive surgery in ovarian cancer? * Whether a single low dose of esketamine administered would relief the postoperative sleep disturbance, postoperative recovery? Researchers will compare the esketamine to a placebo (normal saline) to see if the esketamine works to reduce the postoperative depressive symptoms. Participants will: * Receive either 0.2 mg/kg esketamine or placebo infused intravenously after induction of general anesthesia. * The preoperative Patient Health Questionnaire 9 (PHQ-9) scale was used to verify the symptoms suggestive of depression.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cytoreductive Surgery | — | UNRESOLVED | — |
| Depressive Symptom | — | UNRESOLVED | — |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| esketamine | Drug | — | UNRESOLVED |
| placebo | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- the esketamine group
- interventionNames
- Drug: esketamine
- type
- PLACEBO_COMPARATOR
- label
- the placebo group
- interventionNames
- Drug: placebo
Primary outcomes (1)
- measure
- the incidence of postoperative depressive symptoms after cytoreductive surgery in ovarian cancer
- timeFrame
- on postoperative day 3
- description
- The postoperative depressive symptoms are assessed using the preoperative Patient Health Questionnaire 9 (PHQ-9) scale. The range of this scale is 0-27, and a standard threshold score of 10 or higher indicates symptoms of depression.
Secondary outcomes (25)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * undergoing cytoreductive surgery for ovarian cancer under general anesthesia * ASA physical status I-III * Ages 18-80 years Exclusion Criteria: * Patients taking anti-psychotic medications * Contraindications to esketamine * Language barrier * Inability to provide consent
References
Publications (0)
Data not yet available